Navigation Links
MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
Date:3/13/2008

Combined data from two Phase 3 trials show clinical success rates

statistically equivalent to oral antibiotic therapy

WELLESLEY HILLS, Mass., March 13 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) announced today the presentation of a poster entitled "Topical versus Systemic Antimicrobial Therapy for Treating Infected Diabetic Foot Ulcers: A Randomized, Controlled, Double-Blinded, Multicenter Trial of Pexiganan Cream." The poster will be presented at the Diabetic Foot Global Conference 2008 in Los Angeles on March 13 to 15 by Benjamin A. Lipsky, MD, FACP, FIDSA, Professor of Medicine, University of Washington and Director, Primary Care Clinic, VA Puget Sound Health Care System.

The poster presents results of two Phase 3 clinical studies, individually and combined, comparing the efficacy of an investigational topical antimicrobial peptide preparation, pexiganan acetate cream, against systemic therapy with an oral fluoroquinolone antibiotic, ofloxacin, for mildly infected diabetic foot ulcers. The authors conclude, in part, that, "The rates of clinical cure or improvement (the primary outcome of the trial) for topical pexiganan and oral ofloxacin were statistically equivalent for the combined studies."

Dr. Lipsky commented that, "To my knowledge, these combined studies are the largest on treatment of diabetic foot infections ever conducted, the only ones that have compared these two routes of therapy, and the first to demonstrate the efficacy of a topical antimicrobial in treating diabetic foot infection in active-controlled trials. Furthermore, having an effective topical therapy available as an alternative to systemic treatment focuses attention on the wound and, in the case of pexiganan, uses a new antimicrobial, while avoiding adverse systemic effects and the promotion of antibiotic resistance."

"We are very pleased that these newly analyzed data are being presented for the first time a
'/>"/>

SOURCE MacroChem Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
2. Synbiotics Corporation Announces Human Submission for FluDetect(R)
3. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
4. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
5. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
6. Inclinix Announces New Patent for Expert System Platform
7. Genzyme Announces Presentation of New Positive Data on Carticel(R)
8. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
9. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... has been appointed chief financial officer of the company, ... previously executive vice president and chief financial officer of ... company.  Mr. Clerkin was part of a senior team ... in its sale to Perrigo, a pharmaceutical manufacturer, in ...
(Date:7/22/2014)... LOUIS , July 22, 2014  According to ... time their children spend on digital devices. An AOA ... ages of 10 and 17 estimate they use an ... However, a separate AOA survey of parents revealed that ... an electronic device for that same amount of time. ...
(Date:7/22/2014)... LOS ANGELES , July 22, 2014  NeuroSigma, ... sciences company focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, today announced that enrollment ... external trigeminal nerve stimulation (eTNS) as adjunctive therapy for ... trial is being conducted at the Olive View-UCLA Medical ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
(Date:7/22/2014)... Antonio, TX (PRWEB) July 22, 2014 Dr. ... Designed with existing patients and new visitors in mind, one ... clean, modern and visual layout that makes navigation very easy. ... make the experience of going to the dentist affordable, convenient ... , One helpful new feature is an appointment scheduling system ...
(Date:7/22/2014)... Indianapolis, IN (PRWEB) July 22, 2014 ... benefits advisory organization, announces that Les McPhearson, an insurance ... serve as CEO effective immediately and be based in ... Calise, said, "I am delighted that Les chose to ... is perfectly qualified to address the many challenges facing ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, 2014 (HealthDay ... in the veins of the legs appear no different in ... risk of bleeding and average hospitalization bills that are three ... finds. The standard treatment for these clots -- known ... compression stockings. The other, more expensive treatment delivers medication directly ...
(Date:7/22/2014)... 22, 2014) The American Society of Hematology (ASH) ... School of Medicine, and Robert P. Hebbel, MD, of ... Ernest Beutler Lecture and Prize for their significant research ... The Ernest Beutler Lecture, named for the late Ernest ... for more than 50 years, is a two-part lectureship ...
(Date:7/22/2014)... research at the University of Utah,s John A. Moran ... of Eye Research (ISER) as the recipient of the ... Award in Retina Research., The award recognizes lifetime achievement ... contribution to the understanding of vitreoretinal diseases or disorders. ... ISER Biennial Meeting in San Francisco, where Marc will ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2
... Rostock Center for the study of Demographic Change, have ... be //soon reduced, if the trend of low participation ... ,The Rostock Center is a research institution, ... for Demographic Research and the University of Rostock. The ...
... lead in a global ,program to catalogue human mutations in ... access//. ,For a sample of the expected ... professor at the division of human genetics at the University ... a family who suffered from a heredity eye disease, which ...
... A Geography professor of Kansas State University, Doug Goodin, ... of land use and land cover //changes on human ... uses, combines remote sensing with other types of data, ... Along with other scientists he recently discussed this subject ...
... Chicago – The extended use of anabolic androgenic steroid ... // Gingival enlargement occurs when the tissues ... is a fertile environment for bacteria to grow, which ... that AAS abusers had statistically significant levels of gingival ...
... of misconception about Cannabis and its effects. It is widely ... // Such misrepresentations of the drug have resulted in making ... Karolinska Institute in Sweden have unearthed the harmful effects of ... ingredient in cannabis. It was found that the brain of ...
... medical specialist, NHS can be freed from its’ problems, ... before they are implemented. // It is amply clear ... make matters worse for the deprived and under privileged ... led to low morale among Doctors and NHS staff. ...
Cached Medicine News:Health News:Demographic Change Demand a New Life-Course for Aging Society 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 3Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2Health News:A connection between gingival enlargement and steroid abuse 2
Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
Hardy pituitary spoon, bayonet, malleable....
... Sundt AVM Micro ... construction, non-magnetic, MRI compatible, ... coiled, high minimum closing ... of small perforating vessels ...
... Cougar is an Anterior Spinal Implant system. ... approximating that of cortical bone. The result ... requirements of anterior column support, while optimizing ... sharing design. Incorporates an anatomic design with ...
Medicine Products: